Aprea Q1 net loss $3.3M ($0.22/sh); cash $46.5M; APR-1051 shows two partial responses

Aprea Therapeutics, Inc.

Cash and equivalents $46.5M as of Mar 31, 2026, up from $14.6M year-end 2025; runway into Q1 2028.
Operating loss $3.4M for Q1 2026 vs $4.1M in Q1 2025; R&D expense fell to $1.6M from $2.5M.
WEE1 inhibitor APR-1051: two partial responses observed; dose escalation ongoing; ASCO 2026 presentation on May 30.
Oversubscribed $30M private placement closed Mar 31, 2026, led by Soleus Capital to expand APR-1051 enrollment.
ATRN-119 (ATR inhibitor) monotherapy paused; evaluating combination approaches including with radiation.

item 2.02item 8.01item 9.01

Source: SEC EDGAR

accession 0001104659-26-059734

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.